Karas Eric 4
4 · ARS Pharmaceuticals, Inc. · Filed Jun 20, 2025
Insider Transaction Report
Form 4
Karas Eric
Chief Commercial Officer
Transactions
- Sale
Common Stock
2025-06-18$16.00/sh−15,000$240,000→ 7,696 total - Exercise/Conversion
Common Stock
2025-06-18$1.50/sh+15,000$22,500→ 22,696 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-06-18−15,000→ 559,588 totalExercise: $1.50Exp: 2032-05-23→ Common Stock (15,000 underlying)
Footnotes (2)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.
- [F2]Immediately exercisable.